Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Orphan Drugs Companies

Orphan drugs companies focus on the research, development, and manufacturing of pharmaceutical products designed to treat rare and orphan diseases. These companies play a crucial role in addressing unmet medical needs for patients with rare conditions, often providing life-saving or life-improving treatments.

Orphan Drugs Key Companies *Disclaimer: List of key companies in no particular orderLatest Orphan drugs Companies Update

Feb 2023: On Friday, Sun Pharmaceutical Industries announced that the U.S. health agency had given its company permission to distribute a generic drug used to treat multiple myeloma. According to a statement from Sun Pharma, the U.S. Food and Drug Administration has given the business final approval for the generic lenalidomide capsules in various dosages. Sun Pharma and Celgene Corporation reached a deal in June 2021 to end the patent litigation pertaining to Sun Pharma's generic lenalidomide capsules. As part of the settlement agreement, Celgene licensed Sun Pharma the patents needed to produce and market specific, restricted amounts of generic lenalidomide capsules in the United States starting in March 2022.

Oct 2023: On Friday, Sun Pharmaceutical Industries announced that the U.S. health agency had given its company permission to distribute a generic drug used to treat multiple myeloma. According to a statement from Sun Pharma, the U.S. Food and Drug Administration has given the business final approval for the generic lenalidomide capsules in various dosages. Sun Pharma and Celgene Corporation reached a deal in June 2021 to end the patent litigation pertaining to Sun Pharma's generic lenalidomide capsules. As part of the settlement agreement, Celgene licensed Sun Pharma the patents needed to produce and market specific, restricted amounts of generic lenalidomide capsules in the United States starting in March 2022. Furthermore, about 800 patients were enrolled in INSPIRE, an observational trial that is still underway and aims to determine the safety and efficacy of Alofisel in patients with complex CPF.

List of Orphan drugs Key companies in the market

F. Hoffmann-La Roche AG (Switzerland)

Mylan (US)

Celgene Corporation (US)

Novartis AG (Switzerland)

Biogen (US)

Takeda Pharmaceutical Company Limited (Japan)

Merck KGaA (Germany)

Eli Lilly And Company (US)

Sanofi (France)

Janssen Services LLC (US)

Orphan Drugs Market Highlights:

Orphan Drugs Market Size

Orphan Drugs Market Trends

Orphan Drugs Market Analysis

Orphan Drugs Market Share

Orphan Drugs Market Highlights:

Orphan Drugs Market Trends

Orphan Drugs Market Analysis

Orphan Drugs Market Share

Orphan Drugs Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.